Amgen (AMGN)
News
| May 22 | $AMGN 10 k investment is early 80 s pays 5 cool millions todaY by james15 |
| May 22 | Health Care SPDR In Focus Ahead Of Obamacare Decision Benzinga |
| May 22 | watchin OEX Stocks that were sold the most during sell programs: $MRK, $LOW, $EXC, $JPM, $MS, $HNZ, $WAG, $BMY, $PEP, $PG, $BAC, $CL, $AMGN by mrtopstep |
| May 22 | $AFFY $AMGN misleading drug trial by AMGN article http://stks.co/3w3C by Glopolon |
| May 22 | Antichartjunk's W21-D2 Watchlist: http://stks.co/3w2b $BBBY $CYBX $DG $MO $SXCI $TDG $VZ $WFM $FIRE $GNC $LQDT $TCBI $TSCO $AMT $AMGN $FUL by antichartjunk |
| May 21 | The Definitive Biotech ETF Guide (IBB, XBI, FBT) Benzinga |
| May 21 | Analyst Sees Affymax's (AFFY) Omontys as Comparable to Amgen's (AMGN) Epogen; Raises ... |
| May 21 | Watchlist $AAPL for test of 544 level, $ADSK $WYN $RAX $AMGN $QCOM $JOY $LVS $COH by _TheBlackSwan_ |
| May 19 | 4 Industry Groups Beating the S&P 500 |
| May 18 | /C O R R E C T I O N -- Amgen/ PR Newswire |
Profile
Exchange: NASDAQGS Sector: Healthcare Industry: Biotechnology
Amgen Inc. is an international biotechnology company headquartered in Thousand Oaks, California. Located in the Conejo Valley, Amgen is the world's largest independent biotech firm. The company employs approximately 17,000 staff members. Its products include Epogen, Aranesp, Enbrel, Kineret, Neulasta, Neupogen, Sensipar / Mimpara, Nplate, and Prolia. Epogen and Neupogen were the two most successful biopharmaceutical products at the time of their respective releases. Amgen pioneered the development of novel products based on advances in recombinant DNA and molecular biology, and launched the biotechnology industry’s first blockbuster medicines. Today, as a Fortune 500 company serving millions of patients, Amgen continues to be an entrepreneurial, science-driven enterprise dedicated to helping people fight serious illness.
1 Year Total Return Performance
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Amgen is up 15.44% over the last year vs S&P 500 Total Return up 0.94%, Celgene Corporation up 16.65%, and Biogen Idec up 37.97%.
- AMGN Total Returns
- ^SPXTR Total Returns
- CELG Total Returns
- BIIB Total Returns
Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these AMGN related companies
Pro Strategies Featuring AMGN
Did Amgen make it into our Pro Portfolio Strategies?
AMGN Charts
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Other AMGN Resources
- Company Website
- Wiki Page
- Investor Relations
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
- Technical Charts Chart.ly
- Trading Ideas Benzinga
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| AMGN | 68.36 | -0.55 | -0.80% | 54.05B |
| AMG | 103.26 | -0.13 | -0.13% | 5.351B |
| AMD | 6.075 | -0.09 | -1.38% | 4.308B |
| AMAT | 10.67 | +0.13 | +1.23% | 13.61B |
| AMAG | 13.22 | +0.02 | +0.15% | 279.84M |
| ALX | 386.74 | -2.04 | -0.52% | 1.987B |
| ALVR | 0.485 | -0.01 | -3.00% | 28.12M |
| ALV | 57.69 | +0.48 | +0.84% | 5.121B |
| ALU | 1.56 | +0.08 | +5.41% | 3.442B |
